Alex DeLaney

Alex DeLaney

Associate

Technology Transactions

Dr. Alex DeLaney is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati.

Alex received her Ph.D. in cell and molecular biology from the University of Pennsylvania where she gained research experience in immunology, molecular biology, bacteriology, and parasitology. Her graduate work focused on the role cell death plays in activating the innate immune response to promote host survival during bacterial and parasitic infections.

Experience

Dr. Alex DeLaney is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati.

Education

J.D., University of Pennsylvania Law SchoolOrder of the Coif
Ph.D., Cell and Molecular Biology, University of Pennsylvania
Recipient, National Sciences Foundation Graduate Fellowship
B.S., Physiology and Neuroscience, University of California, San Diego
B.A., Psychology, University of California, San Diego

Admissions

State Bar of California
U.S. Patent and Trademark Office

Credentials

Education

J.D., University of Pennsylvania Law SchoolOrder of the Coif
Ph.D., Cell and Molecular Biology, University of Pennsylvania
Recipient, National Sciences Foundation Graduate Fellowship
B.S., Physiology and Neuroscience, University of California, San Diego
B.A., Psychology, University of California, San Diego

Admissions

State Bar of California
U.S. Patent and Trademark Office

Recent Insights

Client Highlights

On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.

Learn More

Client Highlights

On January 31, 2024, Utah-based Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, announced the completion of a $30 million Series C financing. The financing was led by Todd Pedersen, with continued participation from existing investors. Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction.

Learn More